Katz, Wendy S. and Lesa, Giovanni M. and Yannoukakos, Drakoulis and Clandinin, Thomas R. and Schlessinger, Joseph and Sternberg, Paul W. (1996) A point mutation in the extracellular domain activates LET-23, the Caenorhabditis elegans epidermal growth factor receptor homolog. Molecular and Cellular Biology, 16 (2). pp. 529-537. ISSN 0270-7306 http://resolver.caltech.edu/CaltechAUTHORS:KATmcb96
See Usage Policy.
Use this Persistent URL to link to this item: http://resolver.caltech.edu/CaltechAUTHORS:KATmcb96
The let-23 gene encodes a Caenorhabditis elegans homolog of the epidermal growth factor receptor (EGFR) necessary for vulval development. We have characterized a mutation of let-23 that activates the receptor and downstream signal transduction, leading to excess vulval differentiation. This mutation alters a conserved cysteine residue in the extracellular domain and is the first such point mutation in the EGFR subfamily of tyrosine kinases. Mutation of a different cysteine in the same subdomain causes a strong loss-of- function phenotype, suggesting that cysteines in this region are important for function and nonequivalent. Vulval precursor cells can generate either of two subsets of vulval cells (distinct fates) in response to sa62 activity. The fates produced depended on the copy number of the mutation, suggesting that quantitative differences in receptor activity influence the decision between these two fates.
|Additional Information:||Copyright © 1996, American Society for Microbiology Received 10 May 1995/Returned for modification 27 September 1995/Accepted 7 November 1995 We are grateful to Jim Thomas for providing sa62. We thank Giuseppe Tocchini-Valentini for providing an in vitro mutagenesis protocol, Lily Jiang and Katharine Liu for help in scoring sa62 phenotypes, and Raffi Aroian for many suggestions and stimulating discussions. Some strains were provided by the Caenorhabditis Genetics Center. This work was supported by a grant to P.W.S. from USPHS and by the HHMI, of which P.W.S. is an investigator and W.S.K. is an associate. G.M.L. is a Merck Graduate Fellow. T.R.C. was supported by an Amgen Fund fellowship.|
|Usage Policy:||No commercial reproduction, distribution, display or performance rights in this work are provided.|
|Deposited By:||Archive Administrator|
|Deposited On:||06 Jun 2006|
|Last Modified:||26 Dec 2012 08:54|
Repository Staff Only: item control page